Oppenheimer Upgrades Inspire Medical to Outperform with $85 Target After Q2 Beat
Company raises 2026 guidance and launches cost-cutting plan.
/ 1648 items
#XY↓
Wolfe Research Upgrades Madrigal to Outperform: Sees “Rare Opportunity” After Overdone Sell-Off
Wolfe Research views F4 data timing concerns as overblown after Madrigal’s Q2 beat and strong growth performance.
Leerink Upgrades Replimune to Outperform, Sees High Odds of FDA Approval for Melanoma Therapy
Leerink upgrades Replimune to Outperform with $17 target, citing high odds of FDA accelerated approval for RP-1 melanoma therapy after 10-3 vote.
Twist Bioscience Shares Jump on Record Revenue, Raised Guidance and Path to Profitability
Twist Bioscience shares rose after record $118.4M Q3 revenue (+23% YoY), 14th sequential growth quarter, raised FY26 outlook, and path to EBITDA breakeven.
Krystal Biotech Q2 2026: Solid Growth, Strong Cash, But Revenue Shortfall Triggers Sell-Off
Krystal Biotech shares dropped after Q2 revenue missed forecasts, despite strong earnings, growth, and progress with VYJUVEK sales.
TG Therapeutics Shares Fall on EPS Miss Despite Strong BRIUMVI Sales and Raised Guidance
TG Therapeutics saw strong BRIUMVI sales and raised forecasts, but higher costs caused a major earnings miss, pushing shares lower.